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Eﬀect of Sucralfate on the Relative Bioavailabil ity of Enroﬂoxacin
and Ciproﬂoxacin in Healthy Fed Dogs
K. KuKanich, B. KuKanich, S. Guess, and E. Heinrich
Background: Sucralfate impairs absorption of ciproﬂoxacin and other ﬂuoroquinolones in humans, but no sucralfate–ﬂuo-
roquinolone interaction has been reported in dogs. Veterinary formularies recommend avoiding concurrent administration of
these medications, which might impact compliance, therapeutic success, and resistance selection from ﬂuoroquinolones.
Objectives: To determine whether a drug interaction exists when sucralfate is administered to fed dogs concurrently with
ciproﬂoxacin or enroﬂoxacin, and whether a 2 hour delay between ﬂuoroquinolone and sucralfate aﬀects ﬂuoroquinolone
absorption.
Animals: Five healthy Greyhounds housed in a research colony.
Methods: This was a randomized crossover study. Treatments included oral ciproﬂoxacin (C) or oral enroﬂoxacin (E)
alone, each ﬂuoroquinolone concurrently with an oral suspension of sucralfate (CS, ES), and sucralfate suspension 2 hours
after each ﬂuoroquinolone (C2S, E2S). Fluoroquinolone concentrations were evaluated using liquid chromatography with
mass spectrometry.
Results: Drug exposure of ciproﬂoxacin was highly variable (AUC 5.52–22.47 h lg/mL) compared to enroﬂoxacin (AUC
3.86–7.50 h lg/mL). The mean relative bioavailability for ciproﬂoxacin and concurrent sucralfate was 48% (range 8–143%)
compared to ciproﬂoxacin alone. Relative bioavailability of ciproﬂoxacin improved to 87% (range 37–333%) when sucralfate
was delayed by 2 hours. By contrast, relative bioavailability for enroﬂoxacin and concurrent sucralfate was 104% (94–
115%).
Conclusions and Clinical Importance: A possible clinically relevant drug interaction for the relative bioavailability of cipro-
ﬂoxacin with sucralfate was found. No signiﬁcant diﬀerence in bioavailability was documented for enroﬂoxacin with sucral-
fate. Further research is warranted in fasted dogs and clinical cases requiring enroﬂoxacin or other approved
ﬂuoroquinolones in combination with sucralfate.
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Enroﬂoxacin is a ﬂuoroquinolone with a goodspectrum for gram-negative bacteria, some gram-
positive, and intracellular bacteria.1 Enroﬂoxacina was
the ﬁrst ﬂuoroquinolone developed for and labeled for
use in dogs. Recently, an approved bioequivalent gener-
icb formulation of enroﬂoxacin has become available.
Enroﬂoxacin is partially metabolized to ciproﬂoxacin in
dogs, which is an active metabolite and contributes to
the antimicrobial activity of enroﬂoxacin.2,3 Generic
formulations of human labeled ciproﬂoxacin have been
investigated in dogs; however, oral absorption of cipro-
ﬂoxacin tablets by dogs is variable.4
Some dogs require gastroprotection and ﬂuoro-
quinolones concurrently. Sucralfate is a frequently pre-
scribed gastroprotectant that dissociates into sucrose
octasulfate and aluminum hydroxide, which has antacid
eﬀects. Dosing recommendations of sucralfate for dogs
are derived from human medicine and based on empirical
practice in veterinary medicine. Sucralfate is often admin-
istered to dogs as an oral suspension, supported by a
study ﬁnding fragments of sucralfate tablets in canine
feces after oral administration of sucralfate tablets.5
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Abbreviations:
AUC area under the curve extrapolated to inﬁnity
AUC extrap % AUC extrapolated to inﬁnity
C treatment group receiving ciproﬂoxacin alone
Cl/F clearance per fraction of the dose absorbed
CS treatment group receiving concurrent ciproﬂoxacin and
sucralfate
C2S treatment group receiving ciproﬂoxacin followed
2 hours later by sucralfate
CMAX maximum plasma concentration
CV coeﬃcient of variation
E treatment group receiving enroﬂoxacin alone
ES treatment group receiving concurrent enroﬂoxacin and
sucralfate
E2S treatment group receiving enroﬂoxacin followed
2 hours later by sucralfate
MRT mean residence time extrapolated to inﬁnity
TMAX time to maximum plasma concentration
T1/2 terminal half-life
lg microgram
lL microliter
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A drug interaction is an altered pharmacologic
response to a drug caused by concurrent administration
of other drugs, and can be pharmacokinetic (absorption,
distribution, metabolism, elimination), pharmacodynamic
(antagonistic, synergistic), or pharmaceutic (incompatible
drugs) in nature.6 Current veterinary formularies cite a
potential interaction between sucralfate and both ﬂuoro-
quinolone and tetracycline antimicrobials, caused by
binding of the aluminum component of sucralfate with
the antimicrobial, resulting in non-absorbable chelate
complexes and decreased bioavailability of the antimicro-
bial.7,8 Interactions between sucralfate and both doxycy-
cline and minocycline have been veriﬁed in dogs5,9;
however, research to validate an interaction of sucralfate
with ﬂuoroquinolones in dogs has not been reported.
The interaction between ﬂuoroquinolones and sucral-
fate is well documented in humans. The relative
bioavailability of ciproﬂoxacin is 4% compared to
ciproﬂoxacin alone in human volunteers administered
ciproﬂoxacin with sucralfate concurrently.10 Relative
bioavailability improves to 83% when a 2-hour delay is
implemented between oral ciproﬂoxacin and sucralfate,
and to 96% with a 6-hour delay, leading to the recom-
mendation of at least a 2-hour delay.10 Similarly, when
sucralfate and ciproﬂoxacin are administered concur-
rently to healthy human subjects, serum ciproﬂoxacin
concentrations are reduced, with AUC0–12 decreasing
from 8.8 to 1.1 lg h/mL (P < .005).11 This interaction
in humans occurs with other ﬂuoroquinolones, includ-
ing norﬂoxacin, oﬂoxacin, moxiﬂoxacin, sparﬂoxacin,
and ﬂeroxacin.12–16 When norﬂoxacin or oﬂoxacin is
administered 2 hours before sucralfate, no eﬀect on
bioavailability is seen.12 Based on extrapolation from
these human studies, it has been recommended that
sucralfate be delayed up to 2 hours after ﬂuoro-
quinolone administration to dogs.7,8
The purpose of this study was to determine whether
concurrent administration of sucralfate and ﬂuoro-
quinolone (ciproﬂoxacin or enroﬂoxacin) aﬀects the
extent of ﬂuoroquinolone absorption. Ciproﬂoxacin is
not approved for dogs, but was included because of its
known drug interaction with sucralfate in humans.
Enroﬂoxacin was chosen because it is approved and
commonly used in dogs. A second objective was to
determine if administration of the ﬂuoroquinolone 2
hours before sucralfate administration would result in a
diﬀerence in extent of ﬂuoroquinolone absorption.
Materials and Methods
Animals
Five healthy Greyhounds were included in the study. Three
were neutered males and two were spayed females. Their ages ran-
ged from 4 to 5 years old, and body weights ranged from 30.4 to
42.0 kg. The Institutional Care and Use Committee at Kansas
State University approved the study.
Drug Administration and Sample Collection
This study used a randomized crossover design, with three
treatment groups for each ﬂuoroquinolone. All 5 dogs received all
six treatment groups. Ciproﬂoxacin crossovers were performed
ﬁrst, and when completed were followed by enroﬂoxacin cross-
overs. A random numbers table was used to determine the order
of treatments for each dog within each ﬂuoroquinolone crossover.
A washout period of at least 2 weeks was included between
groups.11 Ciproﬂoxacinc treatments included: Group C: ciproﬂoxa-
cin (25 mg/kg PO) alone; Group CS: sucralfate 1 g suspension
administered PO q8h starting 24 hours before ciproﬂoxacin,
administered concurrently with ciproﬂoxacin (25 mg/kg PO), and
sucralfate suspension continued q8h for two additional doses; and
Group C2S: sucralfate one 1 g suspension administered PO q8h
starting 24 hours before ciproﬂoxacin, administered 2 hours after
ciproﬂoxacin (25 mg/kg PO), and sucralfate suspension continued
q8h for two additional doses.
Enroﬂoxacinb treatments included: Group E: enroﬂoxacin
(5 mg/kg PO) alone; Group ES: sucralfate one 1 g suspension
administered PO q8h starting 24 hours before enroﬂoxacin, admin-
istered concurrently with enroﬂoxacin (5 mg/kg PO), and sucral-
fate suspension continued q8h for two additional doses; and
Group E2S: sucralfate one 1 g suspension administered PO q8h
starting 24 hours before enroﬂoxacin, administered 2 hours after
enroﬂoxacin (5 mg/kg PO), and sucralfate suspension continued
q8h for two additional doses.
A target dose of 25 mg/kg ciproﬂoxacinc was obtained using
250 and 500 mg tablets rounding to the nearest whole tablet/s size.
A target dose of 5 mg/kg enroﬂoxacinb was obtained using 22.7
and 135 mg ﬂavored tablets, rounding to the nearest whole tablet/
s size. All dogs were oﬀered enroﬂoxacin tablets for consumption;
and if they did not ingest them on their own, hand-administration
of pills was performed (pilled) by the researchers as suggested on
the drug’s package insert. Sucralfate suspension (200 mg/ml) was
made by suspending one 1 g tablet of sucralfated in 5 mL water
and shaking until fully dissolved.7 Each dog received water
(10 mL) PO by syringe after administration of all medications to
ensure complete swallowing. The dosing protocol for sucralfate
was designed to ensure that all potential for interaction would be
captured during initial oral absorption of ﬂuoroquinolones as well
as absorption that might occur because of enterohepatic circula-
tion. Dogs were not fasted before drug administration; they
received a standard maintenance canine diet calculated for their
daily requirements; water was provided ad libitum. Throughout
the study, all dogs had consistent food consumption patterns daily,
and no changes were made in type or amount of diet oﬀered or
timing of meals.
Blood samples, 3 mL per time point, were collected by jugular
venipuncture before ﬂuoroquinolone administration and at 0.33,
0.67, 1, 2, 3, 4, 8, 12, and 24 hours after ﬂuoroquinolone adminis-
tration. Whole blood was placed into tubes containing lithium
heparin and stored on ice until centrifugation at 3,000 9 g for
15 min; plasma was then stored at 70°C before drug analysis.
Liquid Chromatography/Mass Spectrometry Method
of Analysis for Ciprofloxacin and Enrofloxacin
Plasma concentrations of enroﬂoxacin and ciproﬂoxacin were
determined using liquid chromatographye with mass spectrometryf,
according to previously published methods.17 Brieﬂy, 0.1 mL of
plasma was added to 0.4 mL methanol containing 0.1% formic
acid and 500 ng/mL of the internal standard norﬂoxacin. The
samples were vortexed for 5 seconds, centrifuged for 5 minutes at
15 000 9 g, and the supernatant transferred to an injection vial.
The mobile phase consisted of 0.1% formic acid in deionized
water and acetonitrile. A C18 columng achieved separation. The
mass to charge ratio (m/z) of the qualifying and quantifying ions
for enroﬂoxacin were 360 and 245.2, respectively; for ciproﬂoxacin
were 332.2 and 245.2, respectively; and for norﬂoxacin were 320.0
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and 276.3, respectively. The lower limit of quantiﬁcation was
0.01 lg/mL and the standard curves were linear from 0.01 to
5 lg/mL. The interday accuracies of the assay for ciproﬂoxacin
were 97, 91 and 95% and the interday coeﬃcients of variation
were 9.5, 4.2 and 8.0% determined on replicates of 5 each at 0.01,
0.5 and 5 lg/mL. The interday accuracies of the assay for enro-
ﬂoxacin were 98, 99 and 94% and the interday coeﬃcients of vari-
ation were 6.5, 4.0 and 10.4% determined on replicates of 5 each
at 0.01, 0.5 and 5 lg/mL.
Pharmacokinetic Analysis
Pharmacokinetic analyses were performed using computer soft-
ware.h The area under the curve extrapolated to inﬁnity (AUC)
was determined with the linear trapezoidal method, and this was
considered the pivotal parameter for comparison of treatments in
this study. The maximum plasma concentration (CMAX) and time
to maximum plasma concentration (TMAX) were determined
directly from the data. The terminal half-life (T1/2), clearance per
fraction of the dose absorbed (Cl/F), and mean residence time
extrapolated to inﬁnity (MRT) were determined. Relative bioavail-
ability was calculated by comparing the dose-normalized AUC
between the two treatments (ﬂuoroquinolone with and without
sucralfate) using a standard equation18:
Statistical Analysis
Statistical analysis was performed with computer softwarei
using a Friedman repeated measures analysis of variance on ranks
to compare pharmacokinetics parameters of the ﬂuoroquinolone
when administered with sucralfate (either concurrently or delayed)
to when administered alone. A P-value of <0.05 was considered
statistically signiﬁcant.
Results
Actual washout periods between treatment groups in
this study ranged from 4 to 9 weeks, meeting the 2-
week minimum time frame. No dog had measurable
enroﬂoxacin or ciproﬂoxacin in their plasma at time 0
during any treatment group.
The pharmacokinetic parameters for ciproﬂoxacin
administered alone and with sucralfate are presented in
Table 1 and Fig 1. No statistically signiﬁcant (P < 0.05)
diﬀerences in pharmacokinetic parameters were noted
between groups. The AUC of ciproﬂoxacin had a 4-fold
range (5.52–22.47 h lg/mL) when it was administered
alone. This variability continued when ciproﬂoxacin
was administered with concurrent sucralfate (1.57–
17.97 h lg/mL) with a mean relative bioavailability of
48% and three dogs having relative bioavailability
<55%. The AUC of ciproﬂoxacin with sucralfate
delayed 2 hours was 7.60–17.65 h lg/mL with a mean
relative bioavailability of 87%. The dog with the lowest
relative bioavailability in the CS group (8%) also had
the lowest relative bioavailability in the C2S group
(37%); similarly, the dog with the highest relative
bioavailability in the CS group (143%) also had the
highest relative bioavailability in the C2S group
(333%). A post hoc sample size calculation found that
23 dogs would be required to achieve 0.8 power to
detect a 50% change in AUC/Dose
(mean = 0.631 h lg/mL) of ciproﬂoxacin with an alpha
of 0.05 and standard deviation of 0.350 h lg/mL, which
is based on the pharmacokinetics in this study for
group C.
Pharmacokinetic parameters for enroﬂoxacin admin-
istered alone and with sucralfate are presented in
Table 2 and Fig 2. Much less variability in exposure to
enroﬂoxacin was present in this population of dogs as
compared with ciproﬂoxacin, with the AUC of enro-
ﬂoxacin alone having a range of 3.86–7.50 h lg/mL,
and enroﬂoxacin with concurrent sucralfate having a
range of 4.15–7.58 h lg/mL. No signiﬁcant diﬀerences
ðAUCof fluoroquinolone administeredwith sucralfateÞ  ðFluoroquinolone dose administered without sucralfateÞ
ðAUCof fluoroquinolone administeredwithout sucralfateÞ  ðFluoroquinolone dose administered with sucralfateÞ
Table 1. Ciproﬂoxacin pharmacokinetics in dogs (n = 5) administered with ciproﬂoxacin alone (C), with concurrent
sucralfate (CS), and with sucralfate delayed 2 hours (C2S), reported as geometric mean and range.
Variable Units Ciproﬂoxacin (C)
Ciproﬂoxacin
Concurrent Sucralfate (CS)
Ciproﬂoxacin Sucralfate
Delayed 2 hours (C2S)
AUC extrap % 7.5 (3.0–29.6) 5.3 (3.3–16.0) 7.6 (2.9–16.0)
AUC h lg/mL 13.59 (5.52–22.47) 6.52 (1.57–17.97) 11.75 (7.60–17.65)
CMAX lg/mL 1.68 (1.13–2.90) 0.86 (0.21–1.72) 1.58 (1.10–1.61)
TMAX hour 0.92 (0.67–1.00) 0.78 (0.67–1.00) 1.40 (0.67–2.00)
T1/2 hour 6.74 (4.66–12.15) 5.8 (4.9–9.2) 6.8 (4.5–10.4)
MRT hour 9.47 (6.05–18.44) 7.87 (6.44–12.76) 9.11 (6.69–11.95)
Cl/F mL/min/kg 31.20 (16.31–81.59) 64.66 (22.07–269.01) 35.83 (24.53–55.50)
Dose mg/kg 25.4 (22.0–27.9) 25.3 (23.8–27.6) 25.3 (22.9–28.2)
Relative bioavailability % N/A 48 (8–143) 87 (37–333)
AUC extrap, % AUC extrapolated to inﬁnity; AUC, area under the curve; CMAX, maximum plasma concentration; TMAX, time to
CMAX; T1/2, terminal half-life; MRT, mean residence time extrapolated to inﬁnity; Cl/F, clearance per fraction of the dose absorbed; rela-
tive bioavailability, fraction of the ciproﬂoxacin dose absorbed relative to when ciproﬂoxacin was administered alone.
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were documented in the pharmacokinetics of enroﬂoxa-
cin when administered with concurrent sucralfate, as
compared with enroﬂoxacin alone. The mean relative
bioavailability of 104% conﬁrmed that no drug interac-
tion for relative bioavailability was found when
enroﬂoxacin was administered with concurrent sucral-
fate. The mean relative bioavailability of enroﬂoxacin
administered with sucralfate delayed by 2 hours was
128%. A post hoc sample size analysis indicated 4 dogs
would be suﬃcient to detect a 50% change in the AUC/
Dose of enroﬂoxacin with a power of 0.8 and
alpha = 0.05, which is based on the pharmacokinetics
in this study for group E (mean = 1.15 h lg/mL, stan-
dard deviation = 0.23 h lg/mL).
Ciproﬂoxacin was identiﬁed in all dogs after enroﬂox-
acin administration (Table 3, Fig 3). The relative
bioavailability of ciproﬂoxacin after enroﬂoxacin
administration was similar when enroﬂoxacin was
administered with sucralfate (86%) and when enroﬂoxa-
cin was delayed 2 hours (101%). Likewise, the total
exposure (AUC) of ﬂuoroquinolones (enroﬂoxacin +
ciproﬂoxacin) and CMAX of total ﬂuoroquinolones
after enroﬂoxacin was not signiﬁcantly diﬀerent
with regard to timing of sucralfate administration
(Table 4).
Discussion
In this study, the AUCs and relative bioavailability
of ciproﬂoxacin were quite variable. This variability
could have been inﬂuenced in part by factors related to
food consumption and digestion since dogs were not
fasted. However, similar variability in ciproﬂoxacin
pharmacokinetics occurs in dogs fasted for 18 hours,
and thus it is not believed to be related to an interac-
tion from food and might instead be dependent on for-
mulation, drug solubility, and tablet disintegration in
the small intestine.4 Similar to this study using Grey-
hounds in a research facility, it is known that Beagles
with relatively uniform weight and identical housing
and feeding conditions have wide ranges in absorption
of ciproﬂoxacin (32–80%), and thus it is diﬃcult to pre-
dict if an individual dog would be able to absorb cipro-
ﬂoxacin adequately and consistently to achieve clinical
Fig 1. Mean  SD plasma concentrations of ciproﬂoxacin in
dogs (n = 5) administered ciproﬂoxacin alone (●), with concurrent
sucralfate (□), and with sucralfate delayed by 2 hours (■).
Table 2. Enroﬂoxacin pharmacokinetics in dogs (n = 5) administered with enroﬂoxacin alone (E), with concurrent
sucralfate (ES), and with sucralfate delayed 2 hours (E2S), reported as geometric mean and range.
Variable Units Enroﬂoxacin (E)
Enroﬂoxacin Concurrent
Sucralfate (ES)
Enroﬂoxacin Sucralfate
Delayed 2 hours (E2S)
AUC extrap % 1.4 (0.8–2.5) 1.7 (0.9–2.5) 1.9 (1.0–5.1)
AUC h lg/mL 5.58 (3.86–7.50) 5.78 (4.15–7.58) 7.27 (4.09–10.32)
CMAX lg/mL 0.77 (0.48–1.24) 1.07 (0.86–1.23) 1.14 (0.85–1.83)
TMAX hour 2.50 (1–8) 0.98 (0.67–2) 1.52 (0.67–4)
T1/2 hour 3.71 (3.46–4.04) 4.07 (3.39–4.61) 3.99 (3.40–5.16)
MRT hour 6.47 (4.49–9.12) 5.46 (4.39–6.10) 6.07 (4.11–8.50)
Cl/F mL/min/kg 14.77 (11.57–20.31) 14.18 (10.54–19.45) 11.57 (8.22–21.25)
Dose mg/kg 4.94 (4.71–5.21) 4.92 (4.79–5.10) 5.04 (4.93–5.22)
Relative bioavailability % N/A 104 (94–115) 128 (96–186)
AUC extrap, % AUC extrapolated to inﬁnity; AUC, area under the curve; CMAX, maximum plasma concentration; TMAX, time to
CMAX; T1/2, terminal half-life; MRT, mean residence time extrapolated to inﬁnity; Cl/F, clearance per fraction of the dose absorbed; rela-
tive bioavailability, fraction of the dose absorbed relative to when enroﬂoxacin was administered alone.
Fig 2. Mean  SD plasma concentrations of enroﬂoxacin in dogs
(n = 5) administered enroﬂoxacin alone (●), with concurrent
sucralfate (□), and with sucralfate delayed by 2 hours (■).
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success with this medication. Variability in AUC and
bioavailability means that with the same dosing proto-
col to target bacteria with a particular MIC, some dogs
might be underdosed and others overdosed, leading to
potential therapeutic failure or increased adverse eﬀects,
respectively. Furthermore, achieving subtherapeutic ﬂu-
oroquinolone concentrations and drug exposure in some
dogs might contribute to selection or promotion of
antimicrobial resistant organisms within these canine
hosts. Ciproﬂoxacin might be a greater risk for thera-
peutic failure and selection of resistant bacteria than
ﬂuoroquinolones that are consistently absorbed.4 Owing
to the documented variability in absorption, ciproﬂoxa-
cin is not a ﬂuoroquinolone of choice for dogs; ﬂuoro-
quinolones labeled for use in dogs should be used
clinically.
This study documented a decrease in mean AUC
from 13.59 to 6.52 h lg/mL and mean CMAX from 1.68
to 0.86 lg/mL when comparing administration of cipro-
ﬂoxacin alone to administration of ciproﬂoxacin with
concurrent sucralfate. Ranges for these values were
wide, as would be expected based on variability in
ciproﬂoxacin alone, and this likely contributed to lack
of signiﬁcant diﬀerences between these groups. When
relative bioavailability was calculated, the ranges were
also wide as expected, with mean 48% (8–143%) for
concurrent sucralfate and 87% (37–333%) for C2S.
Although outliers inﬂuence the mean with a small sam-
ple size, 3/5 dogs had relative bioavailabilities low
enough to suggest that they could have had an interac-
tion with sucralfate, which would be important clini-
cally; further studies with increased sample size are
needed to determine if this interaction would be statisti-
cally signiﬁcant. Bioavailability >100% can occur
because this is a calculated value based on dose-normal-
ized AUC from two treatments (with and without
sucralfate) owing to intra-individual daily variability in
Table 3. Ciproﬂoxacin pharmacokinetics in dogs (n = 5) administered with enroﬂoxacin alone (E), with concurrent
sucralfate (ES), and with sucralfate delayed 2 hours (E2S), reported as geometric mean and range.
Variable Units Enroﬂoxacin (E)
Enroﬂoxacin Concurrent
Sucralfate (ES)
Enroﬂoxacin Sucralfate
Delayed 2 hours (E2S)
AUC extrap % 12.1 (7.0–23.3) 14.1 (9.6–18.3) 15.3 (9.0–27.8)
AUC h lg/mL 3.55 (2.97–4.49) 3.07 (2.35–4.35) 3.57 (2.30–4.79)
CMAX lg/mL 0.23 (0.17–0.29) 0.22 (0.17–0.28) 0.24 (0.23–0.25)
TMAX hour 4.59 (4.00–8.00) 1.84 (0.67–4.00) 3.48 (1.00–8.00)
T1/2 hour 7.31 (5.76–9.84) 8.13 (6.79–9.22) 8.27 (6.71–11.2)
MRT hour 12.34 (9.31–17.36) 12.17 (9.77–14.07) 12.99 (9.47–18.59)
Relative bioavailability % N/A 86 (74–123) 101 (74–141)
AUC extrap, % AUC extrapolated to inﬁnity; AUC, area under the curve; CMAX, maximum plasma concentration; TMAX, time to
CMAX; T1/2, terminal half-life; MRT, mean residence time extrapolated to inﬁnity; Relative bioavailability, fraction of the dose absorbed
relative to when enroﬂoxacin was administered alone.
Fig 3. Mean  SD plasma concentrations of ciproﬂoxacin in
dogs (n = 5) administered enroﬂoxacin alone (●), with concurrent
sucralfate (□), and with sucralfate delayed by 2 hours (■).
Table 4. Total ﬂuoroquinolone (enroﬂoxacin + ciproﬂoxacin) pharmacokinetics in dogs (n = 5) administered with
enroﬂoxacin alone (E), with concurrent sucralfate (ES), and with sucralfate delayed 2 hours (E2S), reported as geo-
metric mean and range.
Variable Units Enroﬂoxacin (E)
Enroﬂoxacin Concurrent
Sucralfate (ES)
Enroﬂoxacin Sucralfate
Delayed 2 hours (E2S)
AUC h lg/mL 9.15 (6.99–12.00) 8.88 (6.74–11.19) 10.85 (6.39–14.50)
CMAX lg/mL 0.99 (0.65–1.46) 1.97 (1.09–2.85) 2.36 (1.88–2.71)
TMAX hour 2.49 (1.00–8.00) 0.78 (0.67–1.00) 1.06 (0.67–2.00)
Relative bioavailability % N/A 97 (87–120) 119 (91–171)
AUC, area under the curve; CMAX, maximum plasma concentration; TMAX, time to CMAX; relative bioavailability, fraction of the dose
absorbed relative to when enroﬂoxacin was administered alone.
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drug absorption. The maximal value of 333% for C2S
is notably high; however, maximal AUC and CMAX for
C2S group were within range of CS values, suggesting
delayed sucralfate administration does not increase total
drug exposure compared to the ciproﬂoxacin group but
was likely individual variability in ciproﬂoxacin absorp-
tion. On the contrary, one dog had only 8% relative
bioavailability when ciproﬂoxacin was administered
concurrently with sucralfate and his CMAX was
decreased to 10% compared to when he received cipro-
ﬂoxacin alone. Therefore, despite lack of a statistically
signiﬁcant interaction, these data support a clinically
relevant interaction for the relative bioavailability and
verify that ciproﬂoxacin has a potential drug interaction
with sucralfate in dogs.
When sucralfate administration was delayed 2 hours
after ciproﬂoxacin, the AUC, CMAX and relative
bioavailability were improved but not equivalent to
those from ciproﬂoxacin alone. It is possible that a
longer delay, such as 3 or 4 hours, might be more ideal
than the tested 2 hours to minimize this drug interac-
tion and allow for maximal relative bioavailability of
ciproﬂoxacin, if both drugs were clinically indicated.
However, it is also possible that the diﬀerence in magni-
tude between ciproﬂoxacin alone compared to ciproﬂox-
acin with sucralfate delayed 2 hours is just because of
the large variability in ciproﬂoxacin absorption and
pharmacokinetics in dogs. Repeating this study with an
enhanced sample size (23 dogs) to account for the vari-
ability in bioavailability could be performed to deter-
mine if this interaction also reaches statistical
signiﬁcance; however, obtaining funding for such a
large study would be challenging with a drug that is not
approved for use in dogs.
It is an interesting observation that the dog who had
the lowest relative bioavailability in the CS treatment
(8%) also had the lowest relative bioavailability (37%)
in the C2S treatment. In addition, the dog who had the
highest relative bioavailability in the CS treatment
(143%) also had the highest in the C2S treatment
(333%). These observations might indicate that individ-
ual animals will have diﬀering degrees of drug interac-
tions between sucralfate and ciproﬂoxacin, even when
the administration is separated by 2 hours, furthering
the suggestion that sucralfate and ciproﬂoxacin should
not be administered to the same animal (concurrently
or even delayed) as the interaction in an individual dog
is diﬃcult to predict.
The ﬁndings of this study represent a clinically rele-
vant interaction for the relative bioavailability of cipro-
ﬂoxacin because drug eﬃcacy for ﬂuoroquinolones is
best correlated with AUC (as compared to bacterial
MIC or minimum inhibitory concentration); drug expo-
sure (AUC) is correlated with clinical eﬃcacy because
ideal therapeutic target is having AUC:MIC exceed 100
to achieve clinical success.4 The lower mean AUC
(6.52 h lg/mL) and minimum AUC (1.57 h lg/mL) for
the CS group, compared with the C group (mean
13.59 h lg/mL, minimum 5.52 h lg/mL), could directly
impact treatment success since the AUC:MIC is corre-
lated with clinical success. Therefore, the dog with the
lowest drug exposure for CS (AUC=1.57 h lg/mL)
would have a predicted clinical cure for bacterial MICs
of 0.016 lg/mL or lower compared to the lowest drug
exposure in the C group (AUC = 5.52 h lg/mL) with
predicted clinical cures for MICs of 0.06 lg/mL or
lower. With ciproﬂoxacin having a susceptible break-
point of 1 lg/mL for human infections caused by Enter-
obacteriaceae, drug exposure in this study was
approximately 100-fold lower than what would be
expected to meet targeted plasma concentration. There
is not a CLSI breakpoint available for ciproﬂoxacin for
canine infections; thus, the human breakpoint is typi-
cally used. In addition, the AUC:MIC has been associ-
ated with selection of resistant strains when it is <100.19
Therefore, the dog with the minimum AUC value for
CS (1.57 h lg/mL) having a 4-fold lower AUC than the
dog with the minimum AUC for the C group
(5.52 h lg/mL) would have an increased potential for
treatment failure as well as selection and propagation of
resistant bacteria.
Throughout the study, no dog had measurable ﬂuo-
roquinolone in their plasma at time 0 for any treatment
group, verifying that no carryover eﬀect was docu-
mented from previous therapy. This was not unex-
pected, as we had targeted and maintained a minimum
2 week washout time between treatment groups.11
No signiﬁcant diﬀerences were seen when AUC and
relative bioavailability were compared between groups
receiving enroﬂoxacin alone and receiving enroﬂoxacin
with concurrent or delayed sucralfate. Although Table 2
shows higher CMAX, AUC, and relative bioavailability
means for the concurrent (ES) and delayed (E2S)
sucralfate groups than the enroﬂoxacin alone group (E),
these ﬁndings were not statistically diﬀerent and their
ranges overlapped. Since post hoc sample size analysis
found that only 4 dogs would have been needed to
identify a statistical diﬀerence if it was present for a
50% change in the AUC, caution should be used not to
overinterpret these trends or to conclude that bioavail-
ability is actually improved with sucralfate administra-
tion. Lack of diﬀerence in AUC or relative
bioavailability when sucralfate was administered con-
currently with enroﬂoxacin compared to enroﬂoxacin
alone suggests a potential lack of a clinically relevant
drug interaction on the relative bioavailability of enro-
ﬂoxacin. This was an unexpected ﬁnding but has clinical
importance, suggesting that canine owners might no
longer need to separate administration of enroﬂoxacin
and sucralfate, which could lead to better compliance
for both medications.
It is unclear why enroﬂoxacin absorption was not
aﬀected by sucralfate in dogs, even though ciproﬂoxacin
appeared to be aﬀected in dogs, and many ﬂuoro-
quinolones have been documented to have this interac-
tion in human studies.10–16 The authors hypothesize this
diﬀerence could be related to the chemical structure of
enroﬂoxacin, which might make it less vulnerable than
other ﬂuoroquinolones to complex formation with the
aluminum in sucralfate. Speciﬁcally, it is hypothesized
that the additional methyl group on enroﬂoxacin might
interfere with the chelation site of aluminum. A similar
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explanation, related to the additional ﬂuorine atoms at
positions 8 and 1 reducing potential for complex forma-
tion, has been proposed for why ﬂeroxacin was found
to have only a modest interaction with sucralfate when
administered to human volunteers.16,20 A sample size
analysis indicated only 4 dogs would be needed to
achieve a power of 0.8 to document a 50% change in
AUC (relative bioavailability) with an alpha of 0.05,
suggesting this study had enough dogs enrolled to docu-
ment a clinically relevant interaction if it was truly pre-
sent. However, further studies with larger numbers of
dogs with naturally occurring bacterial infections should
be performed to conﬁrm this ﬁnding. Further studies
with additional ﬂuoroquinolones approved for use in
dogs would also be helpful to further evaluate for exis-
tence of this interaction and need for separation of
these medications in the clinical setting.
One dog in the enroﬂoxacin alone group had a
lower than expected CMAX (0.48 lg/mL). The low
CMAX appears to have occurred because of slow drug
absorption with a TMAX at 8 hours. However, the
extent of absorption appeared to be unaﬀected, as this
dog had an AUC of 5.55 h lg/mL for enroﬂoxacin,
and this was the pivotal parameter measured for com-
parison of bioavailability in this study. All dogs were
fed before drug administration; this dog ate his meal
quickly and completely, whereas other dogs ate more
slowly throughout the morning during sample collec-
tion. It is hypothesized that this diﬀerence in meal
consumption might have resulted in the slower than
expected drug absorption in this dog. A veterinary for-
mulary and the website of a manufacturer recommend
administration of enroﬂoxacin on an empty stomach
or before feeding.8,21 However, the approved label
does not state to administer enroﬂoxacin to dogs
fasted, and speciﬁcally states that the tabletsb used in
this study (ANADA 200–551) can be oﬀered with food
which is the same recommendation as in the package
insert for the pioneer producta (NADA 140–441).22,23
For this study, dogs were not fasted in attempt to
reﬂect clinical use and to identify a potential clinical
drug interaction. Dogs maintained consistent feeding
patterns throughout the study; thus, if a food–drug
interaction existed it would be expected to aﬀect each
treatment groups’ results equally. Lack of a fasted
group for each treatment is a limitation of the study
and further studies in both fed and fasted dogs are
warranted to fully eliminate a food interaction as the
cause of decreased AUC and bioavailability of cipro-
ﬂoxacin in this study.
Ciproﬂoxacin is an unapproved drug in dogs in the
United States. Ciproﬂoxacin was used in this study
because of the well-documented interaction with sucral-
fate in humans, and the authors’ hypothesis that cipro-
ﬂoxacin might also interact with sucralfate in dogs.
Ciproﬂoxacin is an active metabolite of enroﬂoxacin
in dogs and contributes to the antimicrobial eﬃcacy
after administration of enroﬂoxacin. The AUC of cipro-
ﬂoxacin after enroﬂoxacin (4.94 mg/kg PO) was similar
in this study (mean = 3.55, range 2.97–4.49 h lg/mL)
compared to previous studies in dogs (means
2.66  1.03 and 2.27  0.64 h lg/mL)1,3 administered
5 mg/kg PO. Since eﬀects of sucralfate on enroﬂoxacin
pharmacokinetics were not observed, it was expected
that no eﬀects on the formation and pharmacokinetics
of ciproﬂoxacin after enroﬂoxacin administration would
occur. As expected, there were no signiﬁcant diﬀerences
in the AUC or CMAX of ciproﬂoxacin after enroﬂoxacin
when sucralfate was administered concurrently or
delayed by 2 hours. Similarly, the total exposure of
enroﬂoxacin and ciproﬂoxacin was not signiﬁcantly
aﬀected either, again suggesting sucralfate does not pro-
duce a clinically relevant drug interaction when admin-
istered with enroﬂoxacin. However, clinical trials in
dogs with naturally occurring disease should be per-
formed to conﬁrm these ﬁndings.
The stability of enroﬂoxacin and ciproﬂoxacin in fro-
zen (70°C) canine plasma was not assessed, but stud-
ies in human plasma demonstrate ciproﬂoxacin stability
for at least 6 months when stored at 20°C.24 Plasma
samples were analyzed within 6 months of collection in
this study. It is possible that the stability of enroﬂoxa-
cin and ciproﬂoxacin in canine plasma frozen at 70°C
is less than 6 months. However, as previously stated,
the pharmacokinetics of ciproﬂoxacin and enroﬂoxacin
in this study are similar to previous studies. Further
studies should assess the long-term stability of ﬂuoro-
quinolones in canine plasma.
In conclusion, the mean relative bioavailability of
ciproﬂoxacin was decreased to 48%, with individual
variability, when administered concurrently with suc-
ralfate, but was 87% when sucralfate was delayed by
2 hours after ciproﬂoxacin suggesting a clinically rele-
vant drug interaction for relative bioavailability. The
CMAX and AUC of ciproﬂoxacin were quite variable
in this group of dogs, suggesting variable eﬀects are
expected which is consistent with previous studies. By
contrast, enroﬂoxacin was not aﬀected by concurrent
sucralfate administration, and enroﬂoxacin had more
consistent CMAX and AUC within this study group.
The rate, but not extent of enroﬂoxacin absorption,
might be aﬀected by concurrent food; therefore,
administration fasted might produce more consistent
rates of absorption, but further studies are needed to
conﬁrm the eﬀect of food on rates of absorption for
oral enroﬂoxacin in dogs. Further research is war-
ranted to investigate the presence of an interaction
between enroﬂoxacin or other ﬂuoroquinolones labeled
for use in dogs and concurrent sucralfate in a clinical
setting.
Footnotes
a Baytril, Bayer Animal Health, Shawnee Mission, KS
b Enroﬂoxacin Flavored Tablets, Putney, Inc. Portland, ME
c Ciproﬂoxacin, Pack Pharmaceuticals, Buﬀalo Grove, IL
d Sucralfate, Nostrum Laboratories, Inc., Kansas City, MO
e Shimadzu Prominence, Shimadzu Scientiﬁc Instruments, Colum-
bia, MD
f API 3000, Applied Biosystems, Foster City, CA
Sucralfate and Fluoroquinolone Absorption 7
g Waters XBridge, 50 9 2.1 mm, 5 lM, Waters Corporation, Mil-
ford, MA
h Phoenix WinNonlin 5.2, Certara, Princeton, NJ
i SigmaStat 12.5, Systat Software, Inc., San Jose, CA
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